Sage Journals: Discover world-class research

Abstract

The prognosis of local prostate cancer has improved drastically during the past 60 years. Similarly, the prognosis in metastatic stage is constantly improving due to a number of new pharmaceuticals introduced over the past 10 years. Previously, only palliative treatments were available for prostate cancer, but today, there are multiple options for treatment with curative intent: robotic-assisted radical prostatectomy, stereotactic radiotherapy and brachytherapy. Additionally, life-prolonging chemotherapeutic and androgen-suppressive treatments, as well as diagnostic imaging and staging, have improved considerably. This review summarizes the history of the treatment and diagnostics of prostate cancer, with a focus on the past 60 years. The aim was to provide a concise and easy-to-read introduction on the matter for all people that work with prostate cancer, as well as for patients. The literature was thoroughly examined covering the period from the earliest traceable records to the latest state-of-the-art studies.

Keywords

Prostate cancer history diagnostics treatment

Introduction

The evolution of prostate cancer (PC) treatment has been a success story. In the 1960s, 50%−60% of Northern European men diagnosed for PC died of it within 5 years, and the relative survival rate was still well below 70% in the 1980s.^1,2 In 2016, the 5-year relative survival rate was 93.6% in Sweden and 92.4% in Finland.^2,3 In this paper, we will discuss how this remarkable achievement was established by describing key moments in PC discovery and treatment throughout history. The purpose of this review was to provide a concise and easy-to-read introduction on the historical evolution of the treatment and diagnostics of PC. To our knowledge, there has not been a similar review that covers the matter to this depth in over 20 years.⁴ Understanding the progress is both important and interesting not only for urologists, oncologists, radiologists, and pathologists who work with PC, but also for patients with PC and other medical experts, such as nursing staff.

From ancient times until the 20th century

The first person to describe the prostate was probably the Greek Herophilus of Chalcedon in third century BC, who made his career in Alexandria and whose contributions are known only by indirect references made by Galen.^5,6 The discovery of the prostate is usually attributed to the Venetian anatomist Niccolò Massala, who described it in his work Anatomiae: liber introductorius from 1536.^5,7

The earliest biochemically confirmed case of PC occurred in present-day Siberia in the seventh century BC as found in mummified remains of an Iron Age Scythian king exhibiting bone lesions compatible with PC bone metastases.⁸ Biochemical confirmation was performed by detecting positive antibodies against prostate-specific antigen (PSA) and PSA-bound alpha1-antichymotrypsin.⁸ A biochemically unconfirmed case was found as early as 4500 years BC, also in Siberia.⁸

The credit for describing PC has sometimes been given to Londoner surgeon John Adams (1805−1877), who described it as “scirrhous of the prostate gland” in 1853 after a 59-year-old patient had died 3 years after the onset of the disease.^4,9–11 This was the first case in which cancer was confirmed histologically on autopsy.⁹ However, the German S. Beling described a case of PC leading to mortality in 1822, and the French surgeon Tanche described five cases in 1844.⁹ Adams considered the disease to be very rare at the time.^9,10

Prussian-born Theodor Billroth performed the first partial prostatectomy in Vienna in 1867.¹² In 1904, Hugh Hampton Young performed the first radical prostatectomy (RP).^4,12 In both instances, the surgery was performed through the transperineal approach.^4,12 Young subsequently reported the results from 19 prostatectomies, with almost complete symptomatic recovery in 15 patients.¹³ One patient lived beyond 5 years after the operation and was presumed to be cured.¹³ Young also performed surgical castration for two patients, but in this case, the results were considered to be negative.¹³

In 1895, Wilhelm Roentgen discovered X-rays.¹⁴ This was followed by the discovery of naturally occurring radioactivity by Henry Becquerel in the following year through the work he conducted with uranium salts.¹⁵ In 1898, Marie and Pierre Curie discovered radium and polonium.¹⁶ The first attempts to cure prostate cancer with radiation were made 10 years later, when the Frenchman Henri Minet published the first results of treating PC with radium (Ra)-containing tubes inserted through urethral or suprapubic catheters in 1909.^4,17 Therefore, brachytherapy (BT) is actually the oldest form of radiation therapy used to treat prostate cancer. In the next decade, Hugh Hampton Young as well as urologist Octave Pasteau with radium therapist Paul-Marie Degrais published their own results.^4,17 However, early techniques were difficult to perform and painful for the patient, and thus, internal radiation therapy did not gain interest as a treatment modality for many decades.⁴

The first biomarker found to be useful in PC diagnosis (albeit only in the metastatic stage) was prostate-specific acid phosphatase (PAP), which was discovered by Gutman and Gutman in 1938.^18,19 The main events of the modern era are illustrated as a demonstrative timeline diagram in Figure 1.

Figure 1.

The milestones of the development of PC treatment and diagnostics.

Huge steps forwards: The era from the 1940s to the 1980s

In 1941, future Nobel laureates from the University of Chicago, Charles Huggins and Clarence V. Hodges, demonstrated that estrogen injections delayed the progression of metastatic cancer.^20,21 They also showed that testosterone injections accelerate progression.²⁰ In the same year, Huggins and Hodges, along with R.E. Stevens Jr, published their first positive results in patients treated with either pharmaceutics (estrogen) or surgical castration.^4,22

The retropubic approach to prostatectomy was introduced in 1945, when Terrence Millin from All Saints Hospital in London reported the technique.^4,23 Millin’s technique allowed a more accessible route to the pelvic lymph nodes that could be used for staging.⁴ It remained a mainstay of PC surgery for almost 40 years until 1983, when Walsh et al.^24,25 developed a nerve-sparing technique for RP.⁴

Until the 1950s, there were no X-ray tubes that could produce radiation capable of penetrating into deeper tissues such as the prostate, and thus, external beam radiotherapy (EBRT) with X-ray machines was mainly used to treat only superficial malignancies and other medical conditions.^4,26 The period from 1950 onwards is called the megavoltage era of radiation therapy and was characterized by the use of linear particle accelerators and their predecessor, cobalt teletherapy.²⁶ In January 1965, George et al.²⁷ reported the first patients with inoperable PC to be treated with cobalt therapy.⁴ An example of the contemporary EBRT machinery is shown in Figure 2.

Figure 2.

A patient preparing for radiation therapy in Helsinki in 1955, accompanied by a radiation oncology nurse. Photo by Yrjö Lintunen. Published with the permission of Yrjö Lintunen Foundation and Finnish People’s Archives (kansanarkisto.fi).

Later, in 1965, Bagshaw et al.²⁸ published their results of a trial in which 81 patients with inoperable no distant cancer spread (M0) PC were treated by linear supervised EBRT. The 5-year survival rate was 54%, which was considered excellent at the time.²⁸ Bagshaw’s trial was followed by several others, and by the early 1980s, EBRT had become an acceptable treatment modality for PC.^29,30 The development of intensity-modulated radiation therapy (IMRT) was based on the work by Anders Brahme and others at Karolinska Institute, Stockholm, in the 1980s.^31,32 It became a mainstay of EBRT in the treatment of PC decades later.³²

Interest in brachytherapy resumed in the 1970s, when Basil Hilaris and Willet Whitmore Jr, working for Memorial Sloan Kettering Cancer Center, reported a new technique utilizing iodine-125 isotopes.^4,17 Their technique did not require any image guidance.^4,17 Although the method was initially popular, it was later discarded due to the high rate of long-term failure and complications.^4,17 In the 1980s, Hans Henrik Holm from Denmark developed a technique in which brachytherapy seeds were implanted through transrectal ultrasound (TRUS) guidance, which finally led to a breakthrough in the technique and its adaptation to clinical practice.^4,17

Androgen deprivation from the 1970s to the 1980s

The structure of luteinizing hormone releasing hormone (LHRH) and the methods for synthesizing it were discovered by a research group led by Andrew V. Schally from Tulane University School of Medicine and published in 1970 and 1971.³³ For this discovery, Schally was awarded a Nobel prize in 1977.⁴ Sandow et al.³⁴ demonstrated that treatment with an LHRH analog suppressed testosterone production in rats after an initial surge in 1978. A research group including Schally, among others, demonstrated the beneficial effect of LHRH analog treatment in patients with prostate cancer in 1982.³⁵ The first LHRH analogs approved for commercial use in PC were buserelin and leuprolide in 1984.³⁶ LHRH analogs remain one of the most commonly used alternatives for androgen deprivation therapy (ADT) in the treatment of PC to date.

After the discovery of the androgen receptor in 1968, this receptor was also a tempting target for drug developers.³⁷ However, the first antiandrogen, cyproterone, proved to be unsuccessful since it crossed the blood-brain barrier and blocked the androgen receptors of the brain (leading to increased secretion of LH) in addition to blocking the receptors in the testicles.⁴ This issue was overcome by adding an acetate group to the molecule, thus creating cyproterone acetate, which was approved by the Food and Drug Administration (FDA) for the treatment of PC in 1989.⁴

Although the first chemotherapy agents for cancer, aminopterin and nitrogen mustard, were introduced in the 1940s,³⁸ PC remained an obstacle for chemotherapeutics for a long time. The first chemotherapeutic agent that was found to be useful for PC was estramustine in 1981.³⁹ Estramustine acts as a microtubule-stabilizing agent but also has estrogenic properties and is in fact a derivative of estradiol formed through an addition reaction with nor nitrogen mustard.^39–41 Although estramustine improved biochemical recurrence-free survival (BRFS), it was not shown to be clearly beneficial in regard to overall survival.³⁹ In addition, troublesome side effects, such as nausea and cardiovascular toxicity, also limit its use.⁴²

Advancements in diagnostics from the 1960s to the 1980s

In diagnostics, this 40-year era is especially remembered for the Gleason histopathological grading system published by Donal F. Gleason in 1966.^43–45 It gradually replaced the preceding Broders classification system from 1926.⁴⁶ PSA was discovered in 1979 by a research team led by Ming Chang Wang from Roswell Park Cancer Institute in Buffalo, New York.^47,48 Eight years later, Stamey et al.⁴⁹ demonstrated its usefulness as a biomarker in PC and benign prostate hyperplasia.⁴⁸ PSA’s sensitivity greatly exceeded that of PAP and was also found to be useful in local staging diagnostics.⁴⁹ PSA testing as a method of evaluating treatment response became a clinical practice in the United States in the 1980s and became used as a diagnostic tool in the following decade.⁵⁰

The systematic biopsy technique was introduced in 1989 by Hodge et al.^51,52 In this technique, the urologist biopsies particular anatomical sites systematically under TRUS guidance, even if there were no lump or abnormal firmness palpable.⁵¹ The systematic technique improved the sensitiveness of detecting PC and replaced the previous techniques which relied on urologist’s palpation findings and ultrasound interpretation.^51,52 The systematic technique still recommended additional targeted biopsies of the suspicious areas.⁵¹ The original technique included six cores.^51,52 The 12-core system became a standard approximately 15 years later.⁵²

In the field of imaging, the principles of using radioisotopes to detect metastases were also introduced in the 1960s.^53,54 The technique of producing bone scintigraphy images by detecting metastable technetium-99 isotopes with gamma cameras was introduced by Subramanian and McAfee in 1971 and is still in use today.^53,54 In the same year, the first patients were imaged with computer tomography invented by Sir Godfrey Hounsfield and Alan M. Cormack, Nobel laureates of 1979.⁵⁵ MRI imaging was introduced in 1973 by Paul Lauterbur, Nobel laureate of 2003.⁵⁵

The past 30 years: The revolution of chemotherapy, nuclear medicine and more

In 1996, a new chemotherapeutic, mitoxantrone, was introduced to treat metastatic castration-resistant PC (mCRPC).⁵⁶ However, mitoxantrone was shown to improve only palliative endpoints and not overall survival (OS).⁵⁶ The groundbreaking year was 2004, when the SWOG 99-16 and TAX-327 trials showed that docetaxel improved OS either in combination with estramustine or alone.^57,58 According to current knowledge, the added value of estramustine seems to be low compared with its increased toxicity,⁵⁹ and it is rarely used. In 2015, the E3805 study (which is often also referred to as the “CHAARTED” trial) showed that docetaxel was also beneficial for metastatic hormone-sensitive prostate cancer (mHSPC).^60,61 The only other chemotherapeutic that has been shown to improve OS in metastatic PC is cabazitaxel, which is a taxane chemically similar to docetaxel.⁶² It was shown to improve survival in mCRPC as a second-line treatment after docetaxel failure compared with palliative mitoxantrone in the TROPIC trial in 2010.⁶³ Both taxanes exert their cytotoxic effect on cancer cells by stabilizing microtubules.⁶⁴

In ADT, the first LHRH antagonist to be approved was abarelix in 2003.⁶⁵ Two years later, the drug was withdrawn due to concern over hypersensitivity reactions.⁶⁵ However, other LHRH antagonists, such as degarelix and relugolix, remain on the market.⁶⁶ They have the benefit of avoiding the “flare” reaction associated with LHRH agonists, although other benefits remain unclear, and no long-term suspensions are available, meaning at least monthly injections are needed.⁶⁶

Unlike LHRH antagonists, a novel group referred to as androgen receptor pathway inhibitors (ARPIs) was introduced in the 2000s and has been shown to improve survival compared to conventional treatments in mCRPC, mHSPC and nonmetastatic castration-resistant PC (nmCRPC).⁶⁶ ARPIs include abiraterone acetate, enzalutamide, apalutamide, and darolutamide.⁶⁶ Enzalutamide, apalutamide and darolutamide resemble first-generation antiandrogens in their mechanism of action but bind with greater affinity to ARs and hinder the receptor’s translocation into the nucleus, unlike first-generation antiandrogens.⁶⁷ Abiraterone acetate is different and mainly affects the production of extragonadal androgens.⁶⁸ Abiraterone and enzalutamide were the first to be approved (in mCRPC) in 2013.³⁹ The key drug trials of the present millennium are summarized in Table 1. Recently, darolutamide became the first ARPI to demonstrate a survival benefit in combination treatment with docetaxel in mHSPC with the results from the ARASENS trial from 2022.⁶⁹

Table 1.

The key drug trials of the 21st century summarized.

Trial name	Stage	Intervention versus control	End-result	Year	Refs
SWOG 99-16	mCRPC	Docetaxel + estramustine versus mitoxantrone	Docetaxel becomes approved for mCRPC	2004	55
TAX-327	mCRPC	Docetaxel versus mitoxantrone	Docetaxel becomes approved for mCRPC	2004	56
IMPACT	mCRPC	Sipuleucel-T versus placebo*	Sipuleucel-T shown useful in mCRPC	2010	112
COU-AA-301	mCRPC	Abiraterone versus placebo**	Abiraterone approved for mCRPC after treatment failure with docetaxel	2012	113
AFFIRM	mCRPC	Enzalutamide versus placebo**	Enzalutamide approved for mCRPC after treatment failure with docetaxel	2012	114
ALSYMPCA	mCRPC	Radium-223 dichloride versus placebo**	Radium-223 dichloride approved for mCRPC after treatment failure with docetaxel	2013	72
TROPIC	mCRPC	Cabazitaxel versus mitoxantrone**	Cabazitaxel approved for mCRPC after treatment failure with docetaxel	2013	115
COU-AA-302	mCRPC	Abiraterone versus placebo*	Abiraterone approved for docetaxel-naïve mCRPC patients	2015	116
E3805 (‘CHAARTED’)	mHSPC	Docetaxel + ADT versus ADT	Docetaxel shown useful in high burden mHSPC	2018	117
LATITUDE	mHSPC	Abiraterone versus placebo	Abiraterone becomes approved for mHSPC	2019	118
PROfound	mCRPC	Olaparib versus enzalutamide/abiraterone*	Olaparib approved for patients with BRCA or ATM mutations	2020	119
PREVAIL	mCRPC	Enzalutamide versus placebo*	Enzalutamide approved for docetaxel-naïve mCRPC patients	2020	120
PROSPER	nmCRPC	Enzalutamide versus placebo	Enzalutamide becomes approved for nmCRPC	2020	121
ARAMIS	nmCRPC	Darolutamide versus placebo	Darolutamide becomes approved for nmCRPC	2020	122
VISION	mCRPC	Lutenium-177-PSMA-617 versus standard of care**	Lutenium-177-PSMA-617 approved for mCRPC	2021	71
SPARTAN	nmCRPC	Apalutamide versus placebo	Apalutamide becomes approved for nmCRPC	2021	123
TITAN	mHSPC	Apalutamide versus placebo	Apalutamide becomes approved for mHSPC	2021	124
ARASENS	mHSPC	Darolutamide + docetaxel versus docetaxel	Darolutamide shown useful in combination treatment of mHSPC	2022	67
ARCHES	mHSPC	Enzalutamide versus placebo	Enzalutamide shown to increase survival in mHSPC	2022	125

mCRPC: metastatic castration-resistant PC; mHSPC: metastatic hormone-sensitive PC; nmCRPC: nonmetastatic castration-resistant PC; PSMA: prostate-specific membrane antigen.

Prior docetaxel, **after treatment failure with docetaxel.

The era of prostate-specific membrane antigen and nuclear medicine

In 1987, Horoszewicz et al.⁷⁰ from the State University of New York identified a novel antigen in the LNCaP cell line. In 1994, this antigen was named prostate-specific membrane antigen (PSMA) by Israeli et al.⁷¹ Thirty years later, radiolabelled PSMA molecules are becoming a standard in both PC imaging and anticancer therapy of mCRPC.^72,73 In diagnostic imaging, PSMA PET/CT scans have been performed since approximately 2012 and have been determined to improve both sensitivity and specificity in staging when compared with MRI, standard PET, scintigraphy or CT.⁷² The use of the modality continues to increase.

In 2013, the ALSYMPCA trial first showed that radioactive isotopes could also be used to treat mCRPC.⁷⁴ The trial used radium-223.⁷⁴ The VISION trial in 2021 used a radioactively labelled PSMA molecule (lutetium-177-PSMA-617) that further increased survival.⁷³

Developments in precision medicine and immuno-oncology

Although the present era in general oncology has been a triumph for precision medicine drugs,⁷⁵ developments in the treatment of PC have remained modest at best.⁷⁶ However, some steps forward have been taken. Currently, the European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN^®) and American Urology Association (AUA) recommend genetic testing when possible, at least in metastatic PC.^66,77,78 The poly ADP-ribose polymerase (PARP) inhibitor olaparib was shown to increase the survival of BRCA1/BRCA2/ATM mutation carriers with mCRPC in the PROfound trial in 2020.⁷⁹

In immuno-oncology, success has been even more limited. FDA approved sipuleucel-T in the treatment of minimally symptomatic mCRPC patients in 2010.⁸⁰ This “cancer vaccine” manufactured from the patient’s own cancer cells is not available in Europe.^66,80 The usual immuno-oncologic approaches based on industrially manufactured cancer antibodies have not been proven to improve survival thus far. A phase II study showed promising results with pembrolizumab,⁸¹ but the first phase III study was discontinued due to negative intermediate results.⁸²

The past few decades of curative treatments and active surveillance

In both PC surgery and radiotherapy, advancing technology has played a major role. Laparoscopic prostatectomy techniques were developed in the early 1990s as an alternative to Walsh’s technique.⁸³ Robotic-assisted prostatectomy (RAP) was introduced in approximately 2001,^83,84 and while Walsh’s technique remains equal in OS and other primary endpoints,⁶⁶ RAP seems to reduce operative bleeding and increase surgeon comfort.^84,85 Other developments in the RP field have been the introduction of salvage radiotherapy in patients with biochemical failure,⁸⁶ as well as adjuvant radiotherapy for those with negative features after surgery, such as positive margins or extracapsular extension.⁸⁷

In EBRT, advances in radiotherapy machinery have enabled more accurate dose planning. First, image guidance systems have become available, meaning more accurate patient positioning at every treatment visit.⁸⁸ Second, the treatment areas can now be designed with more asymmetrical borders thanks to intensity-modulated radiotherapy (IMRT) or volumetric arc therapy (VMAT) techniques, sparing healthy tissues.^89,90

The developments in EBRT technology leading to more accurate dose planning have also encouraged the investigation of higher doses per fraction.⁹¹ In the 2010s, moderate hypofractionation with a 2.5−3.4 Gy fraction size was investigated in four trials,^92–94 three of which reported noninferior toxicity and survival results.^92–94 In 2019, a Cochrane meta-analysis concluded that moderate hypofractionation is indeed noninferior.⁹⁵ Since moderately hypofractionated therapy is more cost effective with equal outcomes,⁹⁶ it is currently the gold standard of EBRT recommended by the EAU.⁶⁶

The reporting of quality of life (QoL) results started to become mainstream in the 1990s.⁹⁷ Since both RP and EBRT for PC decrease the patient’s QoL at least in some ways,⁹⁸ the question of how to prevent or delay the negative impacts on patient QoL was raised, as low-risk cancers are unlikely to affect the patient’s OS.⁹⁹ As a response, the concept of active surveillance of local PC was developed to defer possibly needless active treatment, supported by the randomized trial ProtecT, which showed that deferring treatment until it was deemed necessary did not decrease survival in low- or intermediate-risk PCs.¹⁰⁰ The concept of active surveillance or monitoring has since been integrated into both European and American guidelines.^66,77

Further developments in diagnostics

A groundbreaking year in the pathological grading of PC was 2005, when the International Society of Urological Pathology (ISUP) decided that Gleason scores below 5 should not be used.¹⁰¹ Although the 2005 conference did not directly comment against the use of the Gleason 5 score,¹⁰¹ its use gradually declined. For example, in Sweden, the use of the Gleason 5 score declined from 7.4% of cancerous biopsy samples to 0.9% in 2011.¹⁰²

Since Gleason scores were now only reported from 6 or more and patterns 1−2 were not used, the 2014 ISUP conference proposed a new classification system, which reclassified Gleason scores 6−10 into corresponding ISUP grade groups 1−5.¹⁰³

A major development in PC diagnostics in the 2010s was the performance of MRI prior to biopsy to reduce the number of needless biopsies.⁶⁶ The European Society of Urogenital Radiology (ESUR) released a version of the PI-RADS^® classification system for prostate MRI lesions in 2012.¹⁰⁴ Since the 2010s the techniques that incorporate MRI findings, TRUS and palpation findings (so called cognitive fusion biopsies), as well as directly MRI-guided biopsies have become a golden standard in PC diagnostics,^66,105 even though the systematic biopsies are still recommended in addition except for selected patients with prior negative biopsies.⁶⁶

Discussion: The future

Overall, the treatment of PC has taken huge leaps forwards. In Finland, the reported cancer-specific survival of local cases in 2020 was approximately 98% 5 years after diagnosis.¹⁰⁶ With these results, it may be best for future research to focus the limited resources on finding solutions to improve the prognosis of high-risk and metastatic cases. As the past 10 years have proven, the treatment of metastatic PC is constantly improving and providing promising results for future patients.

In EBRT, stereotactic body radiation (SBRT) has been a topic of interest over the past 10 years.^107,108 This ultra hypofractionated form of radiotherapy with a fraction size ⩾3.5 Gy has not been inferior in terms of survival thus far,^66,107 although long-term data are still needed. However, the present data show it to have inferior QoL in the short-term compared with conventional radiation,¹⁰⁷ which raises questions as to whether it could replace moderately hypofractionated radiation.

In brachytherapy, high-dose rate BT (HDR BT) with temporarily implanted catheters has been investigated in recent decades as an adjuvant therapy with EBRT in a study conducted in Mount Vernon Hospital, UK.¹⁰⁹ While HDR BT boost improved BRFS, it did not improve OS even in the final results after 12 years.¹⁰⁹ Prostate cancer-specific survival data were not collected.¹⁰⁹ There was no difference in toxicity.¹⁰⁹ If BT is to develop any further, these types of adjuvant treatments reducing the number of hospital visits required for EBRT even further would be one option. BT boosts could still be useful in selected patients, such as those who are younger than an average PC patient, have few comorbidities and would benefit from improved BRFS, which would reflect survival perhaps only after 15–20 years. This remains a question for future studies.

In surgery, the usefulness of prostatectomy for the primary tumor in oligometastatic disease has been debated, and retrospective studies have shown promising results.¹¹⁰ The results for EBRT have been promising in the STAMPEDE and HORRAD trials, with a benefit in newly diagnosed patients with a low-tumor burden in the STAMPEDE trial,^111,112 but a randomized trial has not yet investigated RP.¹¹³ Future trials have been encouraged by the scientific community.¹¹³ Also, minimally invasive and well-tolerated procedures such as photodynamic therapy may challenge active surveillance if proven effective in future trials.¹¹⁴

In the pharmaceutical management of PC, the large majority industry-financed phase II and phase III trials now focus on immunotherapy, precision medicine and theranostics (drugs that combine imaging and diagnostics similar to Lu-177-PSMA-617).¹¹⁵ One trial whose final results are waited in the near future, is the TRITON3 investigating PARP-inhibitor rucaparib in metastatic PC.¹¹⁶ Recently it was shown to improve progression-free survival against the drug of physician’s choice.¹¹⁶ In the imaging, the desire to find new radiotracers, as well as further investigate PSMA PET/CT are likely to remain as a matter of interest. One promising tracer is a bombesin antagonist gallium-68-RM2 which may provide added value in detecting bladder and pancreatic metastases.¹¹⁷ In MRI, radiomics and deep learning models are developed to aid in radiologist’s work.¹¹⁸

PSA screening was a topic of interest between the 1990s and the 2010s. The European Randomized Study of Screening for PC (ERSPC) included eight countries and 182,000 participants who were 55–69 years old.¹¹⁹ There have also been other randomized trials of considerable size.¹²⁰ Despite tremendous effort, PSA screening has been shown to be ineffective in reducing overall mortality and seems to have only a minor effect on cancer-specific survival.¹²⁰ The focus in screening studies has now shifted to MRI-based screening studies, and large trials using this approach are now being conducted, such as GÖTEBORG-2 in Sweden.¹²¹

Limitations

This article is a historical review that aimed to provide a broad introduction on the history of treatment and diagnostics of PC instead of analyzing any particular question in-depth. The authors come from medical background, and no professional historian took part in the writing of the article.

Conclusions

The evolution of local PC treatment has been a triumph of modern medicine, which showed that the prognosis of usually incurable, fatal disease can be overturned in only approximately 60 years. The focus of research has now shifted towards avoiding and deferring the harms of treatment. Metastatic PC remains a challenge, but also its prognosis has steadily improved, and new treatments are introduced at regular intervals. The advancements in the diagnostics, such as PSMA PET/CT and PI-RADS^® classification, aid in the fight against PC and timely treatment choices.

Footnotes

Acknowledgements

The authors would like to thank Yrjö Lintunen Foundation and kansanarkisto.fi for the use of the photo.

Authors contributions

M.L.: conceptualization, investigation, writing – original draft, visualization. P-L.K-L.: conceptualization, writing – review and editing, supervision, project administration.

Availability of data and materials

Not applicable.

Declaration of conflicting interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.L.: a grant from the Finnish Society for Oncology (2022). P-L.K-L.: grants from the Finnish Cancer Foundation, Pirkanmaa Cancer Society and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital. Honoraria from BMS and Merck.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Informed consent

Not applicable.

ORCID iD

Miikka Lehtonen

References

Helgesen

Holmberg

Johansson

, et al. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996; 88(17): 1216–1221.

Finnish Cancer Registry. Cancer statistics [Internet]. https://cancerregistry.fi/statistics/cancer-statistics/ (2022, accessed 3 February 2023).

Ayobi

Johansson

Toorell

, et al. Cancer i siffror 2018: Populärvetenskapliga fakta om cancer [in Swedish] [Internet]. https://www.cancerfonden.Se/cancer-i-siffror (2018, accessed 3 February 2023).

Denmeade

Isaacs

JT.

A history of prostate cancer treatment. Nat Rev Cancer 2002; 2: 389–396.

Goddard

JC.

The history of the prostate, part one: say what you see. Trends Urol Mens Heal 2019; 10(1): 28–30.

Wiltse

Pait

TG.

Herophilus of Alexandria (325–255 BC). Spine (Phila Pa 1976) 1998; 23(17): 1904–1914.

Palmer

Nicolò Massa, his family and his fortune. Med Hist 1981; 25(4): 385–410.

Ghabili

Tosoian

Schaeffer

, et al. The history of prostate cancer from antiquity: review of paleopathological studies. Urology 2016; 97: 8–12.

Lytton

Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol 2001; 165: 1859–1862.

10.

Adams

The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet 1853; 61(1547): 393–394.

11.

Royal College of Surgeons of England. Adams, John (1805–1877) [Internet], https://livesonline.rcseng.ac.uk/ (2009, accessed 22 February 2023).

12.

Sohn

Hubmann

Moll

, et al. Die geschichte der prostatektomie—Von den anfängen bis DaVinci [In German]. Aktuelle Urol 2012; 43(4): 228–230.

13.

Young

HH. XV

. Cancer of the prostate: a clinical, pathological and post-operative analysis of 111 cases. Ann Surg 1909; 50(6): 1144.

14.

Reed

AB.

The history of radiation use in medicine. J Vasc Surg 2011; 53: 3S–5S.

15.

Obaldo

Hertz

BE.

The early years of nuclear medicine: a retelling. Asia Ocean J Nucl Med Biol 2021; 9(2): 207–219.

16.

Mazeron

Gerbaulet

The centenary of discovery of radium. Radiother Oncol 1998; 49(3): 205–216.

17.

Aronovitz

. A century of brachytherapy (from the prostate’s perspective). In: Devlin

(ed.) Brachytherapy: applications and techniques. 2nd ed. New York, NY: Demos Medical Publishing, LLC, 2015, pp. 1–36.

18.

Gutman

EB.

An “acid” phosphatase occuring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938; 17(4): 473–478.

19.

Kong

Byun

Emerging roles of human prostatic acid phosphatase. Biomol Ther 2013; 21: 10–20.

20.

Huggins

Hodges

. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168(1): 9–12.

21.

Hsing

Chu

Stanczyk

FZ.

Androgen and prostate cancer: is the hypothesis dead?

Cancer Epidemiol Biomarkers Prev 2008; 17(10): 2525–2530.

22.

Huggins

Stevens

Jr Hodges

. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate cancer. Arch Surg 1941; 43(2): 223.

23.

Millin

Retropubic prostatectomy: a new extravesical technique. Lancet 1945; 246(6379): 693–696.

24.

Walsh

Lepor

Eggleston

JC.

Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983; 4(5): 473–485.

25.

Walsh

PC.

The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J Urol 2007; 177(5): 1632–1635.

26.

Slater

. From X-rays to ion beams: a short history of radiation therapy. In: Linz

(ed.) Ion beam therapy: fundalmentals, technology, clinical applications. 1st ed. Heidelberg, Dordrecth, London, New York: Springer, 2012, pp. 3–16.

27.

George

Carlton

Dykhuizen

, et al. Cobalt-60 telecurietherapy in the definitive treatment of carcinoma of the prostate: a preliminary report. J Urol 1965; 93(1): 102–109.

28.

Bagshaw

Kaplan

Sagerman

. Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 1965; 85: 121–129.

29.

Reddy

Giri

Mansfield

CM.

External radiation therapy of localized prostatic cancer. J Natl Med Assoc 1984; 76(1): 61–66.

30.

Murphy

Natarajan

Pontes

, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127(5): 928–934.

31.

Webb

The 21st birthday party for intensity-modulated radiation therapy (IMRT); 21 years from 1988-2009; From concept to practical reality. In: IFMBE Proceedings, Munich, Germany: Springer Verlag, 2009, pp. 49–52.

32.

Huh

Kim

History of radiation therapy technology. Prog Med Phys. 2020; 31(3): 124–134.

33.

Schally

Kastin

Arimura

Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 1971; 22(11): 703–721.

34.

Sandow

Von Rechenberg

Jerzabek

, et al. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril 1978; 30(2): 205–209.

35.

Tolis

Ackman

Stellos

, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982; 79(5): 1658–1662.

36.

Allen

Berger

Bristol

, et al. (ed.) Annual reports in medicinal chemistry. Vol. 24. San Diego, CA: Academic Press, Inc., 1989, pp. 351–362.

37.

Davies

Zoubeidi

Targeting androgen receptor signaling: a historical perspective. Endocr Relat Cancer 2021; 28; T11–T18.

38.

Kleinsmith

LJ.

Cancer screening, diagnosis, and treatment. In: Principles of cancer biology: Pearson new international edition. 1st ed. Harlow, UK: Pearson Education Limited, 2014, pp. 226–259.

39.

Quinn

Sandler

Horvath

, et al. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol 2017; 28: 2658–2669.

40.

Garcia

Weinberg

Small

EJ.

Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clin Prostate Cancer 2005; 4(2): 113–117.

41.

Zhao

Huang

. Anticancer hybrids. In: Decker

(ed.) Design of hybrid molecules for drug development. Elsevier Inc., 2017, pp. 193–217.

42.

Perry

McTavish

Estramustine phosphate sodium: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7(1): 49–74.

43.

Gleason

DF.

Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125–128.

44.

Epstein

JI.

Prostate cancer grading: a decade after the 2005 modified system. Mod Pathol 2018; 31(1): 47–63.

45.

Egevad

Montorsi

Montironi

Donald

Gleason, 1920–2008. Eur Urol 2009; 55(5): 1247–1249.

46.

Kweldam

van Leenders

van der Kwast

Grading of prostate cancer: a work in progress. Histopathology 2019; 74: 146–60.

47.

Wang

Valenzuela

Murphy

, et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17(2): 159–163.

48.

Rao

Motiwala

Karim

OMA

. The discovery of prostate-specific antigen. BJU Int 2008; 101: 5–10.

49.

Stamey

Yang

Hay

, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317(15): 909–916.

50.

Catalona

WJ.

History of the discovery and clinical translation of prostate-specific antigen. Asian J Urol 2014; 1: 12–4.

51.

Hodge

McNeal

Terris

, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142(1): 71–74.

52.

Presti

JC.

Prostate biopsy: how many cores are enough?

Urol Oncol Semin Orig Investig 2003; 21(2): 135–140.

53.

Carlson

A glance at the history of nuclear medicine. Acta Oncol (Madr) 1995; 34(8): 1095–1102.

54.

Subramanian

McAfee

JG.

A new complex of 99mTc for skeletal imaging. Radiology 1971; 99(1): 192–196.

55.

Bercovich

Javitt

MC.

Medical imaging: from roentgen to the digital revolution, and beyond. Rambam Maimonides Med J 2018; 9(4): e0034.

56.

Tannock

Osoba

Stockler

, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756–1764.

57.

Petrylak

Tangen

Hussain

MHA

, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.

58.

Tannock

de Wit

Berry

, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.

59.

Qin

Zhang

, et al. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: a systematic review and meta-analysis. Med (Baltimore) 2016; 95(39): e4801.

60.

Sweeney

Chen

Y-H

Carducci

, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8): 737–746.

61.

Hamid

Huang

Wang

, et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol 2021; 32(9): 1157–1166.

62.

Abidi

Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother 2013; 4: 230–237.

63.

De Bono

Oudard

Ozguroglu

, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147–1154.

64.

Smiyun

Azarenko

Miller

, et al. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Cancer Chemother Pharmacol 2017; 80(1): 151–164.

65.

Moul

JW.

Utility of LHRH antagonists for advanced PC. Can J Urol 2014; 21(2 Supp 1): 22–27.

66.

Mottet

Cornford

Briers

, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Edn. presented at the EAU Annual Congress Milan 2023 [Internet]. Arnhem, the Netherlands: EAU Guidelines Office, https://uroweb.org/guidelines/prostate-cancer

67.

Cattrini

Caffo

Olmos

, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers 2022; 14: 1792.

68.

Thakur

Roy

Ghosh

, et al. Abiraterone acetate in the treatment of prostate cancer. Biomed Pharmacother 2018; 101: 211–218.

69.

Smith

Hussain

Saad

, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022; 386(12): 1132–1142.

70.

Horoszewicz

Kawinski

Murphy

GP.

Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7(5B): 927–935.

71.

Israeli

Powell

Corr

, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54(7): 1807–1811.

72.

Farolfi

Calderoni

Mattana

, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med 2021; 62(5): 596–604.

73.

Sartor

de Bono

Chi

, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385(12): 1091–1103.

74.

Parker

Nilsson

Heinrich

, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213–223.

75.

Tsimberidou

Fountzilas

Nikanjam

, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 2020; 86: 102019.

76.

Galazi

Rodriguez-Vida

, et al. Precision medicine for prostate cancer. Expert Rev Anticancer Ther 2014; 14: 1305–1315.

77.

Schaeffer

Srinivas

, et al. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines®): prostate cancer. Version 1.2023 [Internet]. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2023, accessed 9 October 2022).

78.

Lowrance

Breau

Chou

, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol 2021; 205(1): 22–29.

79.

de Bono

Mateo

Fizazi

, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382(22): 2091–2102.

80.

Wei

Fong

Small

EJ.

Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines 2015; 14(12): 1529–1541.

81.

Antonarakis

Piulats

Gross-Goupil

, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 2020; 38: 395–405.

82.

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) plus chemotherapy in patients with metastatic castration-resistant PC [Internet], https://www.merck.com/news/merck-provides-update-on-phase-3-keynote-921-trial-evaluating-keytruda-pembrolizumab-plus-chemotherapy-in-patients-with-metastatic-castration-resistant-prostate-cancer/ (2022, accessed 30 October 2022).

83.

Hakenberg

OW.

A brief overview of the development of robot-assisted radical prostatectomy. Arab J Urol 2018; 16(3): 293–296.

84.

Skarecky

DW.

Robotic-assisted radical prostatectomy after the first decade: surgical evolution or new paradigm. ISRN Urol 2013; 2013: 1–22.

85.

Fan

Zhang

Wang

, et al. Robot-assisted radical prostatectomy using the KangDuo surgical robot-01 system: a prospective, single-center, single-arm clinical study. J Urol 2022; 208(1): 119–127.

86.

Stephenson

Scardino

Kattan

, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25(15): 2035–2041.

87.

Hackman

Taari

Tammela

, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol 2019; 76(5): 586–895.

88.

Dang

Kupelian

Cao

, et al. Image-guided radiotherapy for prostate cancer. Trans Androl Urol 2018; 7: 308–20.

89.

Fischer-Valuck

Rao

Michalski

JM.

Intensity-modulated radiotherapy for prostate cancer. Transl Androl Urol 2018; 7(3): 297–307.

90.

Teoh

Clark

Wood

, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84: 967–96.

91.

Bruner

Pugh

Lee

, et al. NRG oncology/RTOG 0415, phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer: prostate-specific quality of life results. Int J Radiat Oncol Biol Phys 2016; 96(2): S2–S3.

92.

Incrocci

Wortel

Alemayehu

, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016; 17(8): 1061–1069.

93.

Dearnaley

Syndikus

Mossop

, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17(8): 1047–1060.

94.

Catton

Lukka

, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35(17): 1884–1890.

95.

Hickey

James

Daly

, et al. Hypofractionation for clinically localized prostate cancer. Cochrane Database Syst Rev 2019; 2019(9): CD011462.

96.

Hunter

Mauldon

Anderson

Cost-containment in hypofractionated radiation therapy: a literature review. J Med Radiat Sci 2018; 65(2): 148–157.

97.

Staquet

Berzon

Osoba

, et al. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 1996; 5(5): 496–502.

98.

Chen

Wang

, et al. Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. Oncotarget 2017; 8(58): 99057–99065.

99.

Carter

HB.

Management of low (favourable)-risk prostate cancer. BJU Int 2011; 108(11): 1684–1695.

100.

Hamdy

Donovan

Lane

, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15): 1415–1424.

101.

Epstein

Allsbrook

Amin

, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29(9): 1228–1242.

102.

Danneman

Drevin

Robinson

, et al. Gleason inflation 1998–2011: a registry study of 97 168 men. BJU Int 2015; 115(2): 248–255.

103.

Epstein

Egevad

Amin

, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40(2): 244–252.

104.

Barentsz

Richenberg

Clements

, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22(4): 746–757.

105.

Streicher

Meyerson

Karivedu

, et al. A review of optimal prostate biopsy: indications and techniques. Ther Adv Urol 2019; 11: 1756287219870074.

106.

Lehtonen

Heiskanen

Reinikainen

, et al. Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. BMC Cancer 2020; 20(1): 1–8.

107.

Fransson

Nilsson

Gunnlaugsson

, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 2021; 22(2): 235–245.

108.

Tree

Ostler

van der Voet

, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2022; 23(10): 1308–1320.

109.

Hoskin

Rojas

Ostler

, et al. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results. Radiother Oncol 2021; 154: 214–219.

110.

Nason

Hamilton

RJ.

Treating the primary in metastatic prostate cancer: where do we stand?

Curr Opin Support Palliat Care 2019; 13(3): 243–248.

111.

Parker

James

Brawley

, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392(10162): 2353–2366.

112.

Ali

Hoyle

Haran

ÁM

, et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2021; 7(4): 555–563.

113.

Knipper

Graefen

Primary tumor treatment in oligometastatic prostate cancer: radiotherapy versus radical prostatectomy. Eur Urol Open Sci 2022; 35: 68–69.

114.

Azzouzi

Vincendeau

Barret

, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 2017; 18(2): 181–191.

115.

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [Internet], https://clinicaltrials.gov/ (2023, accessed 28 October 2023).

116.

Fizazi

Piulats

Reaume

, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med 2023; 388(8): 719–732.

117.

Cuccurullo

Di Stasio

Mansi

Nuclear medicine in prostate cancer: a new era for radiotracers. World J Nucl Med 2018; 17(2): 70–78.

118.

Deng

Zhong

, et al. Multi-view radiomics and deep learning modeling for prostate cancer detection based on multi-parametric MRI. Front Oncol 2023; 13: 1198899.

119.

Schröder

Hugosson

Roobol

, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366(11): 981–990.

120.

Ilic

Djulbegovic

Jung

, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018; 362: k3519.

121.

Hugosson

Månsson

Wallström

, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med 2022; 387(23): 2126–2137.

The past and present of prostate cancer and its treatment and diagnostics: A historical review

Abstract

Keywords

Introduction

From ancient times until the 20th century

Huge steps forwards: The era from the 1940s to the 1980s

Androgen deprivation from the 1970s to the 1980s

Advancements in diagnostics from the 1960s to the 1980s

The past 30 years: The revolution of chemotherapy, nuclear medicine and more

The era of prostate-specific membrane antigen and nuclear medicine

Developments in precision medicine and immuno-oncology

The past few decades of curative treatments and active surveillance

Further developments in diagnostics

Discussion: The future

Limitations

Conclusions

Footnotes

Acknowledgements

Authors contributions

Availability of data and materials

Declaration of conflicting interests

Funding

Ethics approval and consent to participate

Consent for publication

Informed consent

ORCID iD

References